Curiously, previous studies have indicated that some of the drugs were shown to perform better than placebo on safety: for instance, when compared with placebo, CP, tocilizumab, and ruxolitinib led to reductions in TEAEs in severe COVID-19 patients [88–90]. The gene discussed is CP; the disease is COVID-19.